Posted by Michael Wonder on 19 Sep 2018
NICE rejects Novartis’ CAR-T Kymriah for adult lymphoma
19 September 2018 - The National Institute for Health and Care Excellence has turned down NHS funding for use of Novartis’ CAR-T therapy Kymriah in adults with relapsed or refractory diffuse large B-cell lymphoma.
The draft guidance recommends against its use for adults after two or more lines of systemic therapy, concluding that it is not cost effective for routine funding or use within the Cancer Drugs Fund.
A key sticking point is the fact that there is no data comparing Kymriah (tisagenlecleucel-T) to salvage chemotherapy, the most common treatment currently used, making it difficult to determine the exact benefits of the therapy, NICE said.
